GSK2193874

a transient receptor potential vanilloid 4 (TRPV4) inhibitor

Also Known As:

7-bromo-N-(1-phenylcyclopropyl)-3-((4-piperidin-1-ylpiperidin-1-yl)methyl)-2-(3-(trifluoromethyl)phenyl)quinoline-4-carboxamide

Networked: 8 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - GSK2193874: 8
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 148
      - GSK2193874: 8

Experts

1.	Chen, Yu: 1 article (05/2024)
2.	Cui, Tingting: 1 article (05/2024)
3.	He, Huanhuan: 1 article (05/2024)
4.	Ma, Ninghong: 1 article (05/2024)
5.	Wang, Shuai: 1 article (05/2024)
6.	Wang, Yaru: 1 article (05/2024)
7.	Hara, Hideaki: 1 article (01/2023)
8.	Liao, Wenjing: 1 article (01/2023)
9.	Moriguchi, Yukiko: 1 article (01/2023)
10.	Nakamura, Shinsuke: 1 article (01/2023)

Related Diseases

1.	Lung Injury 11/01/2019 - "In our study, we observe that blockade of TRPV4 using GSK2193874 or HC-067047 greatly improve the pneumonedema, the lung pathologic changes, the up-regulation of proinflammatory cytokines and the neutrophil infiltration in LPS-induced lung injury. "
2.	Heat Stroke (Heatstroke) 05/30/2018 - "Timely GSK2193874 administration may be useful to reduce heatstroke-induced injury. " 05/30/2018 - "But GSK2193874 treatment before heat stress did not improve the symptoms of heatstroke mice. " 05/30/2018 - "GSK2193874 treatment at heatstroke onset reduced cell apoptosis in heatstroke mice." 05/30/2018 - "The results in murine models of heatstroke verified that GSK2193874, as a selected TRPV4 inhibitor, was injected at heatstroke onset, and then reduced the reduction of core temperature, the death rate, wet/dry ratio of the lung, levels of tumor necrosis factor-α (TNF-α) and interleukin (IL)-6, coagulation indicators, the degree of organ injury, and caspase-3/7 activity (P<0.05). "
3.	Seizures (Absence Seizure) 05/07/2024 - "In vivo, we examined the survival rate, behavioral seizures, histopathological alterations, NMDA receptor phosphorylation, as well as the expression of the NLRP3-ASC-caspase-1 complex and downstream inflammatory factors in the POX poisoning model following intervention with the TRPV4 antagonist GSK2193874. "
4.	Pulmonary Edema 11/07/2012 - "Furthermore, in both acute and chronic HF models, GSK2193874 pretreatment inhibited the formation of pulmonary edema and enhanced arterial oxygenation. " 11/07/2012 - "Finally, GSK2193874 treatment resolved pulmonary edema already established by myocardial infarction in mice. "
5.	Poisoning 05/07/2024 - "In vivo, we examined the survival rate, behavioral seizures, histopathological alterations, NMDA receptor phosphorylation, as well as the expression of the NLRP3-ASC-caspase-1 complex and downstream inflammatory factors in the POX poisoning model following intervention with the TRPV4 antagonist GSK2193874. "

Related Drugs and Biologics

1.	Cytokines
2.	HC-067047
3.	Occludin
4.	Caspase 3 (Caspase-3)
5.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
6.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
7.	Interleukins
8.	GSK2798745
9.	N-butanoylsphingosine

Related Therapies and Procedures

1.	Oral Administration